Last reviewed · How we verify
Lipid-Based Artificial Tear
Lipid-Based Artificial Tear is a Artificial tear / Ocular lubricant Small molecule drug developed by University of Seville. It is currently FDA-approved for Dry eye disease / Keratoconjunctivitis sicca.
A lipid-based formulation that mimics the natural tear film to provide lubrication and protect the ocular surface.
Lipid-Based Artificial Tear is a small molecule intervention used to treat various eye conditions, including Dry Eye Syndromes, Keratoconjunctivitis Sicca, and Lacrimal Apparatus Diseases. It is studied in clinical trials for its effects on conditions such as Aberration, Corneal Wavefront, Evaporative Dry Eye, and Keratoconjunctivitis Sicca.
At a glance
| Generic name | Lipid-Based Artificial Tear |
|---|---|
| Sponsor | University of Seville |
| Drug class | Artificial tear / Ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
This artificial tear product uses lipid components to replicate the lipid layer of the natural tear film, which reduces evaporation and provides sustained lubrication to the eye. By restoring the tear film composition, it alleviates symptoms of dry eye disease and protects the corneal and conjunctival epithelium from damage.
Approved indications
- Dry eye disease / Keratoconjunctivitis sicca
Common side effects
- Transient blurred vision
- Eye irritation
- Mild ocular discomfort
Key clinical trials
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- Two Step Haplo With Radiation Conditioning (PHASE2)
- Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies (PHASE2)
- 2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies (PHASE2)
- Comparative Efficacy of Lipid Based Artificial Tears vs Aqueous Based Artificial Tears in Managing EDE (NA)
- Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines (PHASE1, PHASE2)
- Artificial Tears, Tear Lipids and Tear Film Dynamics (PHASE4)
- Immediate Effects of Lipid-Based and Non-Lipid Artificial Tears on Corneal Aberrations (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lipid-Based Artificial Tear CI brief — competitive landscape report
- Lipid-Based Artificial Tear updates RSS · CI watch RSS
- University of Seville portfolio CI
Frequently asked questions about Lipid-Based Artificial Tear
What is Lipid-Based Artificial Tear?
How does Lipid-Based Artificial Tear work?
What is Lipid-Based Artificial Tear used for?
Who makes Lipid-Based Artificial Tear?
What drug class is Lipid-Based Artificial Tear in?
What development phase is Lipid-Based Artificial Tear in?
What are the side effects of Lipid-Based Artificial Tear?
Related
- Drug class: All Artificial tear / Ocular lubricant drugs
- Manufacturer: University of Seville — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Dry eye disease / Keratoconjunctivitis sicca
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing